Authors: Paulussen, M Ahrens, S Lehnert, M Taeger, D Hense, HW Wagner, A Dunst, J Harms, D Reiter, A Henze, G Niemeyer, C Gobel, U Kremens, B Folsch, UR Aulitzky, WE Voute, PA Zoubek, A Jurgens, H

Citation: M. Paulussen et al., Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study, ANN ONCOL, 12(11), 2001, pp. 1619-1630

Authors: Goetz, AW van der Kuip, H Maya, R Oren, M Aulitzky, WE

Citation: Aw. Goetz et al., Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells, CANCER RES, 61(20), 2001, pp. 7635-7641

Authors: van der Kuip, H Goetz, AW Miething, C Duyster, J Aulitzky, WE

Citation: H. Van Der Kuip et al., Adhesion to fibronectin selectively protects Bcr-Abl(+) cells from DNA damage-induced apoptosis, BLOOD, 98(5), 2001, pp. 1532-1541

Authors: Oetzel, C Jonuleit, T Gotz, A van der Kuip, H Michels, H Duyster, J Hallek, M Aulitzky, WE

Citation: C. Oetzel et al., The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X, CLIN CANC R, 6(5), 2000, pp. 1958-1968

Authors: Jonuleit, T van der Kuip, H Miething, C Michels, H Hallek, M Duyster, J Aulitzky, WE

Citation: T. Jonuleit et al., Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines, BLOOD, 96(5), 2000, pp. 1933-1939

Authors: Busse, D Busch, FW Schweizer, E Bohnenstengel, F Eichelbaum, M Fischer, P Schumacher, K Aulitzky, WE Kroemer, HK

Citation: D. Busse et al., Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism, CANC CHEMOT, 43(3), 1998, pp. 263-268